Payment overview · 2025
General Payments
$401.81
16 reported records · 9 companies
Healthcare provider profile · identity verified
Daniel Gordon, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HARTWELL, GA · NPI 1467862813
Verified facts
What the public records show
CMS Open Payments records show Daniel Gordon, M.D. received $401.81 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 47.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $192.36 | 47.9% | 7 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $54.26 | 13.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.33 | 8.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.00 | 6.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.98 | 5.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.36 | 4.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.75 | 4.7% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.72 | 4.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.05 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $274.81 | 13 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $127.00 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $54.26 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.33 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.33 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $25.74 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 285 | 85 |
| Gabapentin | Gabapentin | 222 | 49 |
| Losartan Potassium | Losartan Potassium | 213 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 194 | 56 |
| Lisinopril | Lisinopril | 159 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 46 |
| Tramadol Hcl | Tramadol Hcl | 123 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 121 | 40 |
| Omeprazole | Omeprazole | 106 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 34 |
| Carvedilol | Carvedilol | 102 | 29 |
| Buspirone Hcl | Buspirone Hcl | 92 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 29 |
| Trazodone Hcl | Trazodone Hcl | 92 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 29 |
| Potassium Chloride | Potassium Chloride | 89 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 32 |
| Furosemide | Furosemide | 86 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 81 | 14 |
| Metformin Hcl | Metformin Hcl | 81 | 27 |
| Sertraline Hcl | Sertraline Hcl | 78 | 20 |
| Meloxicam | Meloxicam | 68 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 24 |
| Jardiance | Empagliflozin | 61 | 17 |
| Ozempic | Semaglutide | 61 | suppressed |
| Azithromycin | Azithromycin | 59 | 41 |
| Mounjaro | Tirzepatide | 59 | 12 |
| Januvia | Sitagliptin Phosphate | 58 | 14 |
| Trulicity | Dulaglutide | 58 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 18 |
| Glipizide | Glipizide | 50 | 14 |
| Alprazolam | Alprazolam | 49 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 11 |
| Spironolactone | Spironolactone | 49 | 14 |
| Prednisone | Prednisone | 48 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | suppressed |
| Simvastatin | Simvastatin | 45 | 11 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 11 |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 23 |
| Eliquis | Apixaban | 36 | suppressed |
| Famotidine | Famotidine | 35 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 21 |
| Nystatin | Nystatin | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | 13 |
| Finasteride | Finasteride | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $401.81 · 16 records | ABBVIE INC. | AIRSUPRA, CLOTTRIEVER BOLD CATHETER, Dexcom G6 Transmitter, KEVEYIS, MAVYRET, MOUNJARO, QULIPTA, Qelbree, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error